Acquisition – November 2, 2026
Lund-based Alligator Bioscience has agreed to sell all rights and assets related to its CD40 agonist antibody mitazalimab to Biossil. The deal includes an upfront payment of USD 0.75 million, milestone payments of up to USD 108 million, and royalties on future sales.
Pharma article – November 2, 2026
Bavarian Nordic will donate 75,000 doses of its MVA-BN mpox vaccine to a newly established global mpox vaccine emergency stockpile, and has also been awarded a contract to supply a further 150,000 doses.
In a new job – November 1, 2026
Swedish Cantargia has appointed Monic Stuart, MD, as Chief Medical Officer, and Norwegian radiopharmaceutical company Oncoinvent has named Zuzana Jiráková Trnková, MD, PhD, to the same role.
Acquisition – November 1, 2026
Swedish SenzaGen has agreed to acquire Alcyomics, a UK company that tests drug candidates for immune-related side effects without using animals. The initial price is approximately SEK 28 million, and the deal takes SenzaGen into safety testing of biological drugs such as antibodies and T-cell engagers.
Business Award – October 30, 2026
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award.
Funding – October 30, 2026
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily.
Clinical Trials – October 29, 2026
Sobi’s pozdeutinurad significantly lowered serum uric acid levels in patients with uncontrolled gout, with the effect sustained for a full year, according to new Phase III data from the pivotal REDUCE-2 study. The results will be presented in a late-breaking session at ACR Convergence 2026.
Clinical Trials – October 28, 2026
Copenhagen-based Genmab says its bispecific antibody petosemtamab, given with pembrolizumab, met both primary endpoints in the global Phase III LiGeR-HN1 trial in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma.
Clinical Trials – October 28, 2026
Swedish biotech Vicore Pharma’s Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) has passed a pre-planned futility analysis. The independent Data Monitoring Committee recommended that the trial continue without modification, and topline results remain on track for mid-2027.
Clinical Trials – October 27, 2026
The final clinical study report from DexTech Medical’s study of OsteoDex in treatment-resistant multiple myeloma confirms the earlier preliminary results. No serious adverse events were reported, and the disease stabilized in all patients during treatment.
Clinical Trials – October 26, 2026
Finnish TILT Biotherapeutics has presented Phase Ib results at ESMO 2026 showing that four of nine evaluable patients with platinum-resistant ovarian cancer responded to its candidate TILT-123 combined with immunotherapy and chemotherapy. Two of the patients achieved complete responses.
Clinical Trials – October 26, 2026
Adding Amgen’s Imdelltra (tarlatamab) to AstraZeneca’s Imfinzi (durvalumab) as first-line maintenance treatment reduced the risk of death by 58% compared with Imfinzi alone in extensive-stage small cell lung cancer, according to results from the Phase III DeLLphi-305 trial presented at ESMO 2026.
Confidential
We are currently seeking a driven and relationship-oriented Key Account Manager in the Stockholm area.
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
In a new job – October 28, 2026
Vitrolife Group has appointed Elin Frostehav as President and CEO. She will take up the role as soon as practicable and no later than May 1, 2027. Until then, Rickard Ericsson, Senior Vice President Innovation, is interim CEO from November 1, succeeding Bronwyn Brophy O’Connor.
In a new job – October 27, 2026
Swedish peptide purification company Nanologica has appointed board member Mark Quick as CEO as it shifts its commercial focus toward North America and Europe. The company also plans a rights issue of approximately SEK 110.5 million.
In a new job – October 27, 2026
AlzeCure Pharma’s CEO Martin Jönsson is stepping down. Chief Scientific Officer and co-founder Johan Sandin will take over as acting CEO while the board recruits a permanent successor.
Careers article – October 20, 2026
Stamina, mentors, passion, and a life outside the lab. When Nordic Life Science profiled five leaders from across the region’s life science industry, from investors to a startup founder to two of its leading scientists, each shared advice for people starting out. Their answers had a lot in common.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Pharma Business – October 29, 2026
The US Food and Drug Administration (FDA) has accepted Uppsala-based Orexo’s resubmitted New Drug Application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose. A decision is expected by March 29, 2027.
Financing – October 28, 2026
Following promising Phase IIa results in heart attack patients, the Danish biotech company ResoTher Pharma plans to list on Spotlight Stock Market in Sweden in December 2026. The listing will take place through a reverse takeover of Hunter Capital RTO 1, valuing the combined company at around SEK 333 million.
Agreement – October 27, 2026
Oslo-based Thor Medical has signed a three-year agreement to supply radium-224 and lead-212 to Medicines Discovery Catapult (MDC), a UK life science service for drug discovery. The isotopes will support MDC’s work to speed up the development of radiopharmaceutical cancer therapies in the UK.
MedTech Business – October 29, 2026
Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).
MedTech Business – October 28, 2026
Uppsala-based diagnostics company Gradientech has launched QuickMIC GN02, a new panel for its rapid antibiotic susceptibility testing (AST) system that gives results for hard-to-treat Gram-negative bacteria in 3 hours and 14 minutes. The panel is CE marked under the EU’s IVDR.
Financing – October 27, 2026
Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.
Biotech Business – October 27, 2026
The US Food and Drug Administration has approved Xbrane Biopharma’s Lucamzi (ranibizumab-blrz) as a biosimilar to Lucentis. The approval gives US patients a lower-cost option for treating wet age-related macular degeneration (AMD) and other serious eye conditions.
Biotech Business – October 20, 2026
The US Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI, Alvotech’s biosimilar to Humira, that more than doubles drug substance output per batch at the company’s facility in Reykjavik.
Biotech Business – October 14, 2026
Alvotech and its partner Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to the high-dose retinal disease drug Eylea 8 mg. According to the companies, it is the first known submission of its kind worldwide.
Funding – October 27, 2026
Researchers at Karolinska Institutet have been granted a total of SEK 59 million from the Swedish research council Formas for two new research programs on how climate change affects human health.
Science Award – October 27, 2026
Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.
Science Award – October 27, 2026
Karolinska Institutet researchers Tim Baker and Carl Otto Schell have received the Lancet–Elsevier Foundation Evidence to Impact Award for Essential Emergency and Critical Care (EECC), a set of 40 basic treatments for critically ill patients on regular hospital wards.
This site uses cookies
